0
Skip to Content
Gallop Therapeutics
About Us
Targeting Galectin-9
Clinical Focus
Patients & Physicians
News
Gallop Therapeutics
About Us
Targeting Galectin-9
Clinical Focus
Patients & Physicians
News
About Us
Targeting Galectin-9
Clinical Focus
Patients & Physicians
News
Allison Talbot 1/9/25 Allison Talbot 1/9/25

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Read More
Allison Talbot 4/11/24 Allison Talbot 4/11/24

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Read More
Allison Talbot 3/13/24 Allison Talbot 3/13/24

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

Read More

6 Tide Street
Boston, MA, 02210
info@galloponcology.com

Expanded Access Policy